Saliva test for glucose control

Non-Invasive Salivary Protein Glycosylation as an index for Short-Term Glycemic Control

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/09/046027

Enrollment

200

Registered

2022-09-29

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E089- Diabetes mellitus due to underlying condition without complications

Interventions

Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients attending diabetes clinic defined by their prior diagnosis and their antidiabetic usage 2. Subjects willing to be on Continuous Glucose Monitoring System for 14 days

Exclusion criteria

Exclusion criteria: Children, pregnancy, kidney disease, liver disease or any acute condition

Design outcomes

Primary

Measure	Time frame
Rapid (point-of-care) Saliva test (of Glycosylated Proteome), is a direct measure of 2-week glucose control in diabetes, as it is significantly associated with serum fructosamine, a known biomarker for 7-14 days diabetes control.Timepoint: at base line	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactRao PV

Kumudini Devi Diabetes Research Center, Ramdevrao Hospital

raopaturi@gmail.com9885051110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026